TITLE
Chronic lymphocytic leukemia response to antisense Bcl-2 inhibitor SPC2996: peripheral blood

SUMMARY
Temporal analysis of peripheral blood from 18 relapsed CLL patients treated with a maximum of 6 doses (0.2-6mg/kg) of SPC2996, an antisense molecule targeting the mRNA of Bcl-2 oncoprotein. Results provide insight into the molecular basis of the immunostimulatory effects of SPC2996 in CLL.

ORGANISM
Homo sapiens

PLATFORM
GPL570 : [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

CITATIONS
Dürig J, Dührsen U, Klein-Hitpass L, Worm J et al. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 2011 Apr;25(4):638-47. PMID:  21358717

MICROARRAYP
T
